Department of Inflammation and Immunity.
Department of Quantitative Health Sciences, and.
JCI Insight. 2024 Apr 4;9(9):e174127. doi: 10.1172/jci.insight.174127.
Diagnostic challenges continue to impede development of effective therapies for successful management of alcohol-associated hepatitis (AH), creating an unmet need to identify noninvasive biomarkers for AH. In murine models, complement contributes to ethanol-induced liver injury. Therefore, we hypothesized that complement proteins could be rational diagnostic/prognostic biomarkers in AH. Here, we performed a comparative analysis of data derived from human hepatic and serum proteome to identify and characterize complement protein signatures in severe AH (sAH). The quantity of multiple complement proteins was perturbed in liver and serum proteome of patients with sAH. Multiple complement proteins differentiated patients with sAH from those with alcohol cirrhosis (AC) or alcohol use disorder (AUD) and healthy controls (HCs). Serum collectin 11 and C1q binding protein were strongly associated with sAH and exhibited good discriminatory performance among patients with sAH, AC, or AUD and HCs. Furthermore, complement component receptor 1-like protein was negatively associated with pro-inflammatory cytokines. Additionally, lower serum MBL associated serine protease 1 and coagulation factor II independently predicted 90-day mortality. In summary, meta-analysis of proteomic profiles from liver and circulation revealed complement protein signatures of sAH, highlighting a complex perturbation of complement and identifying potential diagnostic and prognostic biomarkers for patients with sAH.
诊断挑战继续阻碍成功管理酒精相关性肝炎 (AH) 的有效治疗方法的发展,因此需要确定非侵入性的 AH 生物标志物。在小鼠模型中,补体有助于乙醇诱导的肝损伤。因此,我们假设补体蛋白可以作为 AH 的合理诊断/预后生物标志物。在这里,我们对来自人类肝脏和血清蛋白质组的数据进行了比较分析,以鉴定和表征严重 AH (sAH) 中的补体蛋白特征。sAH 患者的肝脏和血清蛋白质组中多种补体蛋白的数量发生了改变。多种补体蛋白可区分 sAH 患者与酒精性肝硬化 (AC) 或酒精使用障碍 (AUD) 患者和健康对照者 (HCs)。血清甘露聚糖结合凝集素 11 和 C1q 结合蛋白与 sAH 强烈相关,在 sAH、AC 或 AUD 患者与 HCs 之间具有良好的区分性能。此外,补体成分受体 1 样蛋白与促炎细胞因子呈负相关。此外,较低的血清 MBL 相关丝氨酸蛋白酶 1 和凝血因子 II 可独立预测 90 天死亡率。总之,对来自肝脏和循环的蛋白质组图谱的荟萃分析显示了 sAH 的补体蛋白特征,突出了补体的复杂失调,并确定了 sAH 患者潜在的诊断和预后生物标志物。